1. Scrip
  2. >>Business
  3. >>Deals
  4. >>Deal Watch

Deal Watch: How Did J.P. Morgan Deal-Making Compare To Prior Years?

 
• By Joseph Haas and Dexter Jie Yan

Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.

Deal Watch 2021
• Source: Shutterstock

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.

The January J.P. Morgan Healthcare Conference is known to bring a wave of biopharmaceutical deal-making, often with a major deal...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal Watch

Deal Watch: GSK To Tap AN2’s Boron Chemistry Approach In Tuberculosis R&D

 
• By Joseph Haas and Sushmita Panda

Also deals involving Lyell/Innovative Cellular, Lilly/Ailux, Dynavax/Vaxart, AVEO/HiberCell, Incyte/Prelude, AmacaThera/Pacira, Roche/Manifold and Chromatin/Purespring.

Deal Watch: AstraZeneca Remains Busy In AI, Via Deals With Immunai, Turbine And Algen

 
• By Joseph Haas and Lisa Takagi

Plus deals involving Takeda/Innovent, Genentech/Ventus, Sanofi/EVOQ, Novo Nordisk/Sumitomo, Lisata/Catalent, Boehringer Ingelheim/Accent, BI/Molcure, tech transfer agreements and more.

Asia Deal Watch: Chugai Teams With Rani On Oral Version Of Rare Disease Antibody Drug

 
• By Joseph Haas, Jung Won Shin, Lisa Takagi, Xu Hu, and Vibha Ravi

Plus deals involving Astellas/Taysha, Haihe/Taiho, AimedBio/Boehringer Ingelheim, Takeda/Nabla, CytoMed/TC BioPharm, Specialised Therapeutics/CanariaBio, UgeneX/AviadoBio, Lupin, Kissei/Searchlight, Kazia/QIMR and Prism/Servier.

Deal Watch: Clywedog, Barinthus To Merge With Focus On Diabetes, Celiac Disease

 
• By Joseph Haas

Plus deals involving Klotho/Turn, BioLineRx/Hemispherian, Dogwood/Serpin, Harrow/Melt, Gossamer/Respira, Lilly/Prellis, BI/TegMine and more.

More from Deals

Novo-Emcure Semaglutide Deal Clever Counter To Indian Rivals, Follows Lilly-Cipla Pact

 
• By Vibha Ravi

Novo Nordisk’s deal with Emcure for semaglutide will launch Poviztra as a second obesity brand in India, improving access to weight loss treatments following a Lilly-Cipla deal for tirzepatide and seems a clever counter to Indian majors planning to launch generic semaglutide next year

MeiraGTx Gene Therapy Catches Lilly’s Eye In $475m Pact

 
• By Kevin Grogan

Deal Snapshot: Eli Lilly has become increasingly interested in genetic treatments for the eye and has secured the rights to a high-profile gene therapy for a rare form of childhood blindness.

Pfizer Wins Out In Metsera Bidding War

 
• By Mary Jo Laffler

Novo backs out, leaving Pfizer to complete its acquisition of the obesity specialist for nearly $3bn more than its initial offer.